MikaLion
@MichalisLiontos
Followers
361
Following
1K
Media
283
Statuses
839
Ασυνάρτητος και ημιτελής. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.
Athens, Greece
Joined March 2009
@UoATherapeutics Team at #ESMOGynae25 with our Head @thanosdimop. We presented 3 posters from our clinical research in ovarian cancer. @MMigkou @MKaparelou @johnntanasis Katerina Aravantinou. @OncoAlert @VuMediHemOnc
0
5
22
Dr. Antonio Gonzalez Martin set perfectly the stage for treatment evolution in HRP patients. Very limited benefit from current CT and maintenance therapy options. Are we ready to explore non chemotherapy regimens for HRP pts? #ESMOGyn25 @myESMO @OncoAlert
2
5
8
RT @thanosdimop: Drs Sonneveld,Terpos,and Gavriatopoulou presenting at EHA 2025 the new EHA EMN guidelines for the treatment of multiple my….
0
11
0
There is at least one greater than me that is in agreement 🙂 @quimmateo What a Great commentary!!! @ASCO @urotoday
0
0
0
Congratulations @g_mountzios for leading this practice changing trial!!.
#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC :. ✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001.✅ improved QoL (dyspnea and cough).✅ 27% vs 62% G3 TRAEs. Grateful to all collaborators, @Amgen science team and above all our pts
0
0
2
RT @g_mountzios: #ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC :. ✅ mOS: 13.6 vs 8.3 mon….
0
80
0
#ASCO25 AMPLITUDE trial changes forever mCSPC patients management:.- Genetic testing for all.- NIRA+ABI+ADT ⬆️ PFS and is the new SoC for BRCA1/2 mut and possibly HRRmut patients (20% of mCSPC). ☑️ Reimburse HRR testing in Greece @OncoAlert @HeSMO_X @urotoday @HellenicUrology
2
8
11
2/2 TRUST study. No molecular data available. PFS increase does not translate into OS benefit. Maybe a signal with longer follow-up? .- Biology of the disease determines survival more than surgery.
0
0
3
1/2TRUST trial announced negative for OS at #ASCO25!! Statistical significant ⬆️ PFS with primary surgery. Effect most striking among those with R0 resections. Conclusions:.- Reassure high quality surgery.- No major change in clinical practice @OncoAlert @ESGO_society @ASCO
0
6
11
No one denies that Nivo-IPi in CM-214 has offered the highest OS rate in 1st line RCC.
0
0
0
SERENA study addition of camizestran at ctDNA positivity for ESR1 mutation increased PFS. No solid conclusions for the clinical importance due to study design. Excellent commentary for the negative implications of this early intervention tactic. @SvarnaAnna @OncoAlert #ASCo25
0
4
5
CAR-T cells therapy makes initial steps towards RCC therapeutic algorithm. An anti-CD70 allogeneic Car-T demonstrated 25% ORR limited to high expressing CD70 tumours. Some responses durable! @ASCO @urotoday @VuMediHemOnc @OncoAlert . Exciting new data #ASCO25
0
7
8
Excellent news for EV-P responders! In EV-302 median DoR 23 months, hope for cure for those in CR ( 3 out of 4) remaining CR long term!! Very informative data by @shilpaonc! Congrats to @jackiebrown_MD for excellent and inspiring discussion. #ASCO25 @urotoday @OncoAlert @eeoogek
0
6
12
Despite these approaches already obsolete by EV-Pembro, CM-901 Ipi-Nivo vs Gem Carbo in Cis- ineligible was STATISTICALLY negative but with clinical meaningful benefit. Almost 30% discontinued IO due to toxicity. #ASCO25 @ASCO @OncoAlert @PGrivasMDPhD
0
5
8
It could be the sandy beach of a Greek island as well, but it’s just the Golden Coast at Lake Michigan. #ASCO2025
0
1
9
The last castle has fallen. First positive phase III IO clinical trial in ovarian cancer!!!! Could PARPi resistance prime for IO efficacy? IO-ADCs combos seem the next rationale apprach for this disease setting. @OncoAlert @ESGO_society @HeSMO_X
merck.com
Study also met secondary endpoint of overall survival (OS) for patients whose tumors express PD-L1 KEYTRUDA® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first...
0
10
16
RT @PGrivasMDPhD: Join @BertrandTOMBAL & me in a fun virtual educational webinar! Link:. @mirrorsmed @mtsiatas @Mi….
us02web.zoom.us
Join this webinar on Wednesday February 26, 18:00 CET, where Petros Grivas and Bertrand Tombal will discuss the latest results of the ARANOTE and ARASENS trials, and the implications of these new...
0
12
0
Best Q&A session ever in #GU25. @MattGalsky @tompowles1 @ERPlimackMD @cnsternberg arguing over best treatment approach in localized Bladder cancer upon presentation of NIAGARA and CM274 updated results!! Excellent discussion from @ERPlimackMD. @PGrivasMDPhD @OncoAlert
0
20
43
#GU25. Mevrometostat, an EZH2 inhibitor plus ENZA vs ENZA in mCRPC, Abi and taxane (50%) pretreated pts:.Combo, ⬆️ rPFS by 8 months!! Increased GI toxicity and alopecia but generally manageable. MEVRO clinical program to start in Greece soon. @UoATherapeutics @EllokGr @OncoAlert
0
3
13